For most of the history of Alzheimer’s disease, there was no way to know whether the pathological changes associated with it were occurring in a living person’s brain until symptoms had already appeared — and often not even then with certainty. Definitive diagnosis required either a PET scan costing several thousand dollars, or a lumbar puncture to analyze cerebrospinal fluid. Neither was practical for routine preventive assessment.

That is now changing, and the pace of change has been remarkable. Over the past several years, a new class of blood-based biomarkers has emerged that can detect Alzheimer’s-related brain changes with a level of accuracy that would have seemed improbable a decade ago. Several of these tests are now commercially available, reimbursable in some contexts, and beginning to enter clinical practice in a meaningful way.

This matters enormously for prevention. If the goal is to intervene before symptoms appear — during the long pre-symptomatic window when lifestyle and medical interventions have the most impact — then we need tools that can detect what is happening in the brain years before a person notices anything is wrong. Blood biomarkers are becoming that tool.

Why Biomarkers Change the Prevention Equation

Alzheimer’s disease is not a condition that begins when symptoms begin. The pathological hallmarks — amyloid-beta plaques and tau tangles — start accumulating in the brain 15 to 20 years before any cognitive change becomes apparent. By the time most people receive a clinical diagnosis, significant and largely irreversible neuronal loss has already occurred.

This is the fundamental problem with waiting for symptoms. It is analogous to discovering atherosclerotic heart disease only after a heart attack — technically correct as a diagnosis, but far too late to have prevented the event.

Blood biomarkers give us a way to look inside the brain during that silent interval. A person who is cognitively normal today but shows elevated amyloid-related markers in their blood is not a person to reassure and send home. They are a person to engage in intensive, evidence-based preventive intervention — sleep optimization, metabolic health management, exercise, targeted pharmacological strategies where appropriate — during the window when those interventions are most likely to matter.

The Key Biomarkers: What Each One Measures

Phosphorylated Tau 217 (p-tau 217)

Of the currently available blood biomarkers, p-tau 217 has emerged as the strongest performer for Alzheimer’s-specific pathology. Tau is a protein that stabilizes the internal structure of neurons. In Alzheimer’s disease, tau becomes abnormally phosphorylated at specific sites and aggregates into neurofibrillary tangles — one of the two defining pathological features of the disease.

P-tau 217 in particular appears to rise early in the Alzheimer’s disease continuum, correlating well with amyloid burden as measured by PET imaging. Multiple large studies, including work published in JAMA and Nature Medicine, have demonstrated that p-tau 217 can distinguish Alzheimer’s pathology from other causes of cognitive change with an accuracy approaching that of cerebrospinal fluid analysis or PET imaging — a meaningful threshold.

Clinically, elevated p-tau 217 in a cognitively normal person does not mean they will inevitably develop Alzheimer’s dementia. It means the underlying pathological process is underway, which changes the risk calculation and the urgency of preventive intervention.

Amyloid 42/40 Ratio

Amyloid-beta is the other defining pathological feature of Alzheimer’s disease. In a healthy brain, amyloid is produced and cleared continuously. In Alzheimer’s disease, a specific form — amyloid-beta 42 — begins to misfold and aggregate into plaques. As this happens, the concentration of amyloid-beta 42 in the blood falls, while amyloid-beta 40 (a shorter, more soluble form) remains relatively stable.

The ratio of amyloid-beta 42 to amyloid-beta 40 is therefore a more reliable signal than either measurement alone. A low 42/40 ratio suggests that amyloid-beta 42 is being sequestered in the brain rather than circulating in the blood — an early indicator of amyloid pathology.

This biomarker is most useful as a screening signal. It is less specific than p-tau 217, meaning a low ratio does not definitively confirm Alzheimer’s pathology on its own, but it raises the signal to pursue more specific evaluation.

Glial Fibrillary Acidic Protein (GFAP)

GFAP is a structural protein released by astrocytes — the support cells of the brain — when they are injured or activated in response to neurodegeneration. Elevated blood GFAP levels reflect ongoing neuroinflammatory processes and astrocyte reactivity, which are present in Alzheimer’s disease but also in other forms of neurodegeneration and brain injury.

GFAP is not Alzheimer’s-specific, but it adds useful information in combination with other markers. Elevated GFAP in the context of abnormal p-tau 217 and amyloid ratio strengthens the signal considerably. It is also a useful marker for tracking neuroinflammatory burden over time — relevant for patients undertaking lifestyle interventions that are intended to reduce inflammation.

Neurofilament Light Chain (NfL)

NfL is a structural protein released into the blood when axons — the long projections of neurons that carry signals — are damaged. It is a marker of neurodegeneration broadly, not specific to Alzheimer’s disease. Elevated NfL is seen in Alzheimer’s, frontotemporal dementia, ALS, multiple sclerosis, and traumatic brain injury, among others.

Its value in the context of Alzheimer’s risk assessment is as a measure of the rate and extent of neuronal injury. A person with normal amyloid and tau markers but elevated NfL may have another process causing neurodegeneration that warrants investigation. A person with Alzheimer’s-specific markers and elevated NfL has evidence of both the disease process and active neuronal damage — a more urgent picture.

NfL also has a role in monitoring. In patients who have been identified as high risk and are pursuing aggressive preventive strategies, a declining NfL trend over time can serve as one indicator that the intervention is reducing ongoing neurodegeneration, though this application is still being validated in research settings.

What an Abnormal Result Means — and Does Not Mean

This is where clinical judgment is essential, and where the direct-to-consumer blood biomarker market creates real risk of harm through misinterpretation.

An elevated p-tau 217 or a low amyloid 42/40 ratio does not mean you have Alzheimer’s disease. It means there is evidence of Alzheimer’s-related pathological processes occurring in your brain. The distinction is not semantic — it has direct implications for how the information should be interpreted and acted upon.

Several important caveats apply to every biomarker result:

No single biomarker is definitive. These tests are interpreted as a panel, in the context of a patient’s age, genetic risk (particularly APOE status), cognitive testing results, family history, and clinical examination. A single elevated marker in isolation changes the probability estimate; it does not make a diagnosis.

False positives exist. Particularly for the amyloid 42/40 ratio, which can be affected by factors including body mass index, cardiovascular disease, and laboratory variation. This is another reason biomarker results require clinical interpretation rather than direct-to-consumer reporting.

Risk is not destiny. Even in individuals with strongly positive biomarkers and APOE4 homozygosity — the highest-risk genetic profile — Alzheimer’s dementia is not inevitable. Lifestyle, metabolic health, sleep, and other modifiable factors influence whether and when pathological processes translate into clinical symptoms. Knowing your biomarker status is most valuable precisely because it creates the opportunity to act on that modifiable risk.

A normal result is not a guarantee. Normal biomarkers at age 48 do not mean the same pathological process will not begin at 55 or 60. For high-risk individuals, repeat testing over time has clinical value.

How Biomarkers Fit Into a Comprehensive Risk Assessment

In my practice, blood biomarkers are one component of a broader picture that includes:

Biomarkers inform this picture; they do not replace it. A patient who is APOE4 positive, has borderline metabolic health, sleeps poorly, and shows elevated p-tau 217 requires a different and more intensive conversation than one who is APOE4 negative with normal biomarkers and excellent metabolic health — even if both are cognitively asymptomatic today.

Who Should Consider Blood Biomarker Testing

There is no universal recommendation for population-level biomarker screening in asymptomatic individuals — the field is still establishing the evidence base for how results should guide management at scale. But in clinical practice, I consider biomarker evaluation particularly relevant for:

Testing is not appropriate as a standalone consumer product without clinical context. It is appropriate as part of a relationship with a physician who can interpret the results, explain what they mean for that specific individual, and — critically — translate the information into a personalized prevention plan.

The Practical Reality

The pace of development in this field is genuinely rapid. Several of these tests have received FDA Breakthrough Device designation and are now available through reference laboratories. Reimbursement is evolving. The clinical guidelines are catching up to the science.

What is already clear is that the era of waiting for symptoms before thinking seriously about Alzheimer’s is ending. The tools now exist to identify the disease process during the window when intervention is most meaningful. The question is whether patients and clinicians will use them.

In my practice, that answer is yes. For patients who are willing to engage with the full picture of their brain health — genetic risk, biomarkers, cognitive baseline, metabolic health, sleep — we can construct a prevention strategy that is genuinely personalized rather than generic. That is a different kind of medicine than most people have experienced. It is the kind that has a chance of actually changing outcomes.

 

Dr. Nadir Bilici is a double board-certified neurologist and lifestyle medicine physician specializing in preventive neurology, Alzheimer’s prevention, and cognitive risk assessment. He sees patients via telehealth nationwide.